A5028928177- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Advanced biosensing and bioanalysis techniques
- Nanowire Synthesis and Applications
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Toxin Mechanisms and Immunotoxins
- Carbon and Quantum Dots Applications
- Cancer Cells and Metastasis
- Nanoplatforms for cancer theranostics
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Animal Virus Infections Studies
- Nanoparticle-Based Drug Delivery
- Cancer Research and Treatments
- Xenotransplantation and immune response
- Peptidase Inhibition and Analysis
- Bacteriophages and microbial interactions
- Neuroblastoma Research and Treatments
- Immune cells in cancer
- Cancer, Stress, Anesthesia, and Immune Response
Guangxi Medical University
2017-2024
Tumor Hospital of Guangxi Medical University
2023
Stomatology Hospital
2023
Target (United States)
2017
Dendritic cell (DC)-based cancer vaccines is a newly emerging and potent form of immune therapy. As for any new technology, there are still considerable challenges that need to be addressed. Here, we investigate the antitumor potential novel liposomal vaccine, M/CpG-ODN-TRP2-Lipo.We developed vaccination strategy by assembling DC-targeting mannose adjuvant CpG-ODN on surface liposomes, which were loaded with melanoma-specific TRP2180-188 peptide as vaccine. M/CpG-ODN-TRP2-Lipo treatment was...
Abstract Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging. We therefore focused on developing nanobody-based CAR-T cells that treat the tumor. CD105 expression upregulated neoangiogenic endothelial and cells. has been developed as drug target. Here we show generation CD105-specific nanobody, an anti-human cells, by inserting sequences anti-CD105...
Here we explored the fusion of dendritic cells (DCs), potent antigen-presenting that initiate primary immune responses, with cancer-associated fibroblasts (CAFs), which are a stromal component needed for tumor progression, aim stimulating T to inhibit growth. Dendritic from bone marrow BALB/c mice were co-cultured CAFs H22 mouse hepatoma cells. found express fibroblast activation protein and α-smooth muscle actin by flow cytometry, Western blotting immunofluorescence. Polyethylene glycol was...
Cancer tissue-specific and nuclei-targeted drug delivery is ideal for the of chemotherapy. However, it has only been achieved in vitro studies mainly due to low efficiency vivo. In this study, we aimed establish an efficient dual-targeted system that targets liver cancer tissue as well nuclei cells vivo.We first synthesized TAT peptide (TATp)-mesoporous silica nanoparticle (MSN) complex (TATp-MSN) generated liposomes carried cancer-specific aptamer TLS11a (TLS11a-LB). We then...
: Adequate recruitment of highly active tumor antigen-specific cytotoxic T lymphocytes (CTLs) remains a major challenge in cancer immunotherapy.
Cytotoxic T‑lymphocyte antigen‑4 (CTLA‑4) is a critical negative regulator of immune responses. CTLA‑4 rapidly upregulated following T‑cell activation, and then binds to B7 molecules with higher affinity than CD28. may abolish the initiation responses T cells by raising threshold signals required for full activation cells, it also terminate ongoing T-cell This regulatory role has led development monoclonal antibodies (mAbs) designed block activity enhancing against cancer. mAbs have several...
Background: Chimeric antigen receptor (CAR) T-cell therapy is practical in treating cancers of hematopoietic origin, but that solid tumors compromises efficacy for the loss recognized by CAR. However, dendritic cell (DC)/tumor fusion vaccines present a spectrum known or unknown tumor antigens to stimulate T expansion and enhanced response. Developing new strategy nanobody-based CAR-T (Nb-CAR-T) cells antitumor activity DC/tumor stimulation would provide guidance more effective therapies....
Abstract Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed death 1 (PD-1) is correlated with dysfunction that confer tumor-mediated immunosuppression. Developing a novel nanobody-based trispecific engager (Nb-TriTE) would be potential strategy to improve therapeutic efficacy. Methods Given nanobodies (Nbs), we first screened Nb targeting fibroblast...
Dendritic cell (DC)-based tumor vaccines are a promising immunotherapeutic method of cancer treatment. However, their therapeutic applications significantly limited by weak immunogenicity, costly culturing steps, and easily degradable properties. Thus, the anti-tumor activity for should be improved. In this study, novel lipid nanoparticle (M/CpG-ODN-H22-Lipo) was developed, which conjugated with synthetic CpG oligodeoxynucleotides (CpG-ODN) mannose then loaded H22 hepatoma lysate. Our data...
The detection of cytotoxic T‑lymphocyte antigen‑4‑positive (CTLA‑4+) T‑cell subgroups in peripheral blood samples and tumor tissues is great significance. In the present study, a rapid, succinct efficient method was designed for CTLA‑4+ human T cells using CTLA‑4‑specific nanobody‑fluorescent carbon quantum dots complex (QDs‑Nb36). QDs‑Nb36 used high sensitivity by flow cytometry or immumofluorescent staining. study demonstrated that novel technique more specific effective ratio compared...
Adoptive cell-based immunotherapy typically utilizes cytotoxic T lymphocytes (CTLs), expanding these cells ex vivo. Such expansion is traditionally accomplished through the use of autologous APCs that are capable interactions with cells. However, incidental inhibitory program such as CTLA-4 pathway can impair cell proliferation. We therefore designed a nanobody which specific for (CTLA-4 Nb 16), and we then used this molecule to assess its ability disrupt signaling thereby overcome negative...
The broader application of adoptive cell therapy (ACT) in cancer immunotherapies (particularly for solid tumors) has always been limited by the immunosuppressive tumor microenvironment (TME) and insufficient targetability effector T cells, resulting unsatisfied therapeutic outcome. Here, we designed a new strategy using aptamer-based immunoliposomes to modify PD-1-silencing which were activated dendritic (DC)/tumor fusion cells (FCs) improve antitumor potency cytotoxic lymphocytes (CTLs/CD8+...
In this research, we studied the therapeutic efficacy of a newly designed fusion protein containing Endoglin single-chain variable fragment and IP10 (Endoglin-scFv/IP10), together with our recently generated TRP2-specific CD8 + CD28 CTLs (CD8 CTLs) in controlling melanoma growth mice. The recombinant Endoglin-scFv/IP10 was expressed E. coli , purified by affinity chromatography, characterized vitro for its chemotactic movement immunoreactivity endoglin-expressing cells. vivo xenografts were...